TRIPLE NEGATIVE BREAST CANCER: A MOLECULAR SKETCH

Triple-negative breast cancer, portrayed by cancers that don't express estrogen receptor (ER), progesterone receptor (PR), or HER-2 gene, represents an essential clinical challenge in light of the fact that these cancer don't react to endocrine treatment or other accessible targeted agents. The metastatic potential in triple-negative breast cancer is like that of other breast cancer subtypes, yet these cancers are connected with a shorter middle time to backslide and demise. One vital objective is thusly the identification of prognostic elements and markers to dependably select high and low risk subsets of patients with triplenegative cancer for distinctive treatment methodologies of subtypes with differential responsiveness to particular agents. However, a solid prognostic marker has been subtle, and markers have been conflictingly valuable. For instance, epidermal growth factor receptor (EGFR) have been investigated, yet there is still an absence of concession to a standard measure or cutoff for EGFR expression levels regarding prognosis. Correspondingly, in light of the fact that triplenegative status is basically utilized as a surrogate for basal-like breast cancer, particular basal markers have been investigated. Chemotherapy remains the backbone of treatment for triplenegative breast cancer, however imperative impediments still should be overcome in the following couple of years if any noteworthy clinical steps are to be made.